Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies.
暂无分享,去创建一个
[1] David H. Miller,et al. A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.
[2] N. Eter,et al. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. , 2008, American journal of ophthalmology.
[3] S. Richards,et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. , 2004, The New England journal of medicine.
[4] D Tripathy,et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Thariat,et al. Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Ariagno,et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. , 1998, The Pediatric infectious disease journal.
[7] M. Pescovitz,et al. Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation , 2003, Clinical transplantation.
[8] E. Keystone,et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.
[9] M. Garovoy,et al. Population Pharmacokinetics and Pharmacodynamics of the Anti-CD11a Antibody hu1124 in Human Subjects with Psoriasis , 1999, Journal of Pharmacokinetics and Biopharmaceutics.
[10] T. Matsushita,et al. No changes in infliximab levels in blood stored for preoperative autologous blood donation , 2008, Modern rheumatology.
[11] T. Vollmer,et al. An open-label safety and drug interaction study of natalizumab (Antegren™) in combination with interferon-beta (Avonex®) in patients with multiple sclerosis , 2004, Multiple sclerosis.
[12] M. Narabayashi,et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] A. le Pape,et al. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. , 2009, Blood.
[14] N. Miyasaka,et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. , 2004, Arthritis and rheumatism.
[15] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] P. Toutain,et al. A preclinical pharmacokinetic/pharmacodynamic approach to determine a dose of GnRH, for treatment of ovarian follicular cyst in cattle. , 2004, Journal of veterinary pharmacology and therapeutics.
[17] J. Kovarik,et al. Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients , 2001, Clinical transplantation.
[18] N. Mendenhall,et al. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Kovarik,et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. , 1997, Transplantation.
[20] A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy , 2007, Modern rheumatology.
[21] S. Crawford,et al. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. , 2001, The Journal of infectious diseases.
[22] L. Norton,et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M. Taniwaki,et al. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] R. Slavin,et al. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. , 2009, The Journal of allergy and clinical immunology.
[25] C. Hudis,et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. , 1999, Seminars in oncology.
[26] B. Nashan,et al. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. , 2002, Transplantation.
[27] M. Schreier,et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. , 1995, Transplantation.
[28] I. Nestorov. Clinical pharmacokinetics of TNF antagonists: how do they differ? , 2005, Seminars in arthritis and rheumatism.
[29] P. Lipsky,et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. , 2000, The Journal of rheumatology.
[30] S. Liao,et al. Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL‐12/23p40, in Patients With Moderate to Severe Plaque Psoriasis , 2009, Journal of clinical pharmacology.
[31] M. Hidalgo,et al. Pharmacokinetics of Cetuximab After Administration of Escalating Single Dosing and Weekly Fixed Dosing in Patients with Solid Tumors , 2006, Clinical Cancer Research.
[32] S. Meri,et al. Complement Activation in Circulation and Central Nervous System after Rituximab (Anti-CD20) Treatment of B-Cell Lymphoma , 2001, Leukemia & lymphoma.
[33] P. Kwon,et al. Population Pharmacokinetics of Efalizumab (Humanized Monoclonal Anti‐CD11a Antibody) Following Long‐Term Subcutaneous Weekly Dosing in Psoriasis Subjects , 2005, Journal of clinical pharmacology.
[34] S. Pyati,et al. Palivizumab Use in Very Premature Infants in the Neonatal Intensive Care Unit , 2004, Pediatrics.
[35] Binodh DeSilva,et al. Bioanalytical Method Validation for Macromolecules in Support of Pharmacokinetic Studies , 2005, Pharmaceutical Research.
[36] Y. Sasaki,et al. Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer , 1999, British Journal of Cancer.
[37] M. Varughese,et al. Pharmacokinetics of CAMPATH-1H in BMT patients. , 2001, Cytotherapy.
[38] F. Breedveld,et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.
[39] K. Gelmon,et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] P. Beer,et al. VITREOUS LEVELS OF UNBOUND BEVACIZUMAB AND UNBOUND VASCULAR ENDOTHELIAL GROWTH FACTOR IN TWO PATIENTS , 2006, Retina.
[41] P. Rutgeerts,et al. Infliximab induces potent anti‐inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease , 2001, Alimentary pharmacology & therapeutics.
[42] D. Czerwinski,et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma , 1994 .
[43] R. Tacey,et al. Development and validation of ELISA for herceptin detection in human serum. , 2004, Journal of immunological methods.
[44] P. Klein,et al. Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer , 2005, Cancer Chemotherapy and Pharmacology.
[45] J. Kovarik,et al. A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations1 , 2002, Transplantation.
[46] J. Kuhlmann,et al. Pharmacokinetics of alemtuzumab and the relevance in clinical practice , 2008, Leukemia & lymphoma.
[47] K. Darcy,et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] E. Vasiliauskas,et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. , 1999, Gastroenterology.
[49] R. Herbst,et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. , 2004, Lung cancer.
[50] F. Vincenti,et al. Pharmacokinetic and Pharmacodynamic Studies of One or Two Doses of Daclizumab in Renal Transplantation , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[51] R. Busuttil,et al. Low serum OKT3 levels correlate with failure to prevent rejection in orthotopic liver transplant patients. , 1990, Transplantation proceedings.
[52] Yvonne S. Lin,et al. Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys , 2008, Cancer Chemotherapy and Pharmacology.
[53] D. Mould,et al. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. , 1997, Transplantation.
[54] M. Sliwkowski,et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers , 1999, Oncogene.
[55] Y. Ohashi,et al. Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B‐cell lymphoma , 2006, Cancer science.
[56] R. Ransohoff,et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function , 2009, Neurology.
[57] G. Klintmalm,et al. A novel three‐dose regimen of daclizumab in liver transplant recipients with hepatitis C: A pharmacokinetic and pharmacodynamic study , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[58] L. Matis,et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. , 1996, Molecular immunology.
[59] A. Joshi,et al. Pharmacokinetic–Pharmacodynamic–Efficacy Analysis of Efalizumab in Patients with Moderate to Severe Psoriasis , 2005, Pharmaceutical Research.
[60] A. Gottlieb,et al. Subcutaneously Administered Efalizumab (Anti-CD11a) Improves Signs and Symptoms of Moderate to Severe Plaque Psoriasis , 2003, Journal of cutaneous medicine and surgery.
[61] N. Fineberg,et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics1 , 2004, Transplantation.
[62] Olivier Heudi,et al. Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. , 2008, Analytical chemistry.
[63] L. Visai,et al. A New Sensitive Enzyme-Linked Immunosorbent Assay (ELISA) for Alemtuzumab Determination: Development, Validation and Application , 2007, International journal of immunopathology and pharmacology.
[64] M. Czuczman,et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[65] S. Perkins,et al. A Phase I Study of 90Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non–Hodgkin's Lymphoma: A Children's Oncology Group Study , 2007, Clinical Cancer Research.
[66] Vinod P. Shah,et al. Workshop/conference report—Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays , 2007, The AAPS Journal.
[67] A. Gottlieb,et al. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis , 2007, Current medical research and opinion.
[68] E. Franssen,et al. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[69] M. Koller,et al. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS , 1999, Neurology.
[70] J. Pulido,et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). , 2007, Ophthalmology.
[71] T. Kishimoto,et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. , 2003, The Journal of rheumatology.
[72] F. Breedveld,et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status , 2008, Clinical Rheumatology.
[73] J. Kovarik,et al. A population pharmacokinetic screen to identify demographic‐clinical covariates of basiliximab in liver transplantation , 2001, Clinical pharmacology and therapeutics.
[74] O. Ramilo,et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. , 2008, The Journal of pediatrics.
[75] Jos H Beijnen,et al. Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma. , 2009, Analytical biochemistry.
[76] J. W. Findlay,et al. Some important considerations for validation of ligand-binding assays. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[77] B. Dijkmans,et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis , 2004, Annals of the rheumatic diseases.
[78] M Taniwaki,et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[79] M. Mochizuki,et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. , 2004, The Journal of rheumatology.
[80] Jeffrey W. Clark,et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma , 2007, Cancer.
[81] A. Thomas,et al. Natalizumab Therapy for Moderate to Severe Crohn Disease in Adolescents , 2007, Journal of pediatric gastroenterology and nutrition.
[82] H. Lui,et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. , 2001, Journal of the American Academy of Dermatology.
[83] D. Mould,et al. Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assay. , 1995, Journal of immunological methods.
[84] R. Kozarek,et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab , 2007, Inflammatory bowel diseases.
[85] Helen X. Chen,et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] D. Wright,et al. Environmental toxicology: Factors affecting toxicity , 2002 .
[87] R. Pounder,et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active crohn's disease , 2001 .
[88] Binodh DeSilva,et al. Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules , 2003, Pharmaceutical Research.
[89] A. Kimball,et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) , 2008, The Lancet.
[90] B. Dijkmans,et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation , 2007, Annals of the rheumatic diseases.
[91] D. Combs,et al. Population Pharmacokinetics of Rituximab (Anti‐CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical Trial , 2005, Journal of clinical pharmacology.
[92] G. Paintaud,et al. Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients , 2008, Therapeutic drug monitoring.
[93] D. Podoloff,et al. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. , 2003, Cancer biotherapy & radiopharmaceuticals.
[94] B. Dijkmans,et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.
[95] J. Pulido,et al. SIX-MONTH STABILITY OF BEVACIZUMAB (AVASTIN) BINDING TO VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER WITHDRAWAL INTO A SYRINGE AND REFRIGERATION OR FREEZING , 2006, Retina.
[96] K. Bendtzen,et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. , 2006, Arthritis and rheumatism.
[97] H. Paulus,et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. , 2003, Clinical therapeutics.
[98] L. V. D. van de Putte,et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. , 2002, The Journal of rheumatology.
[99] L. Czer,et al. Immunologic monitoring of OKT3 induction therapy in cardiac allograft recipients. , 1995, Clinical transplantation.
[100] Xinping Fang,et al. LC-MS/MS approach for quantification of therapeutic proteins in plasma using a protein internal standard and 2D-solid-phase extraction cleanup. , 2007, Analytical chemistry.
[101] P. Rutgeerts,et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease , 2007, Gut.
[102] P. Vereerstraeten,et al. OKT3 serum levels as a guide for prophylactic therapy: a pilot study in kidney transplant recipients , 1994, Transplant international : official journal of the European Society for Organ Transplantation.
[103] K. Gelmon,et al. Trastuzumab and Liposomal Doxorubicin in the Treatment of MCF-7 Xenograft Tumor-Bearing Mice: Combination Does Not Affect Drug Serum Levels , 2005, Pharmaceutical Research.
[104] A. Gottlieb,et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. , 2003, Journal of the American Academy of Dermatology.
[105] J A Parker,et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2001, Critical reviews in oncology/hematology.
[106] F. Lee,et al. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft , 2005, Cancer Chemotherapy and Pharmacology.
[107] Y G Meng,et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. , 1999, The Journal of pharmacology and experimental therapeutics.
[108] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[109] M. Grever,et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[110] J. Baselga,et al. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[111] J. Baselga,et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[112] Edward S. Kim,et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[113] T. Waldmann,et al. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. , 2003, Journal of autoimmunity.
[114] R. Colvin,et al. OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. , 1986, Transplantation.
[115] V. Zagonel,et al. Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. , 2000, Therapeutic drug monitoring.
[116] P. Szurman,et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. , 2008, Ophthalmology.
[117] M. Silverberg,et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[118] J. Kovarik,et al. Disposition and immunodynamics of basiliximab in liver allograft recipients , 1998, Clinical pharmacology and therapeutics.
[119] J. Roberts,et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. , 2000, Transplantation.
[120] R. Dockhorn,et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. , 1997, The Journal of allergy and clinical immunology.
[121] L. Gordon,et al. Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis , 2006, Leukemia & lymphoma.
[122] M. Pescovitz,et al. Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients , 2008, Pediatric transplantation.
[123] C. Constantinescu,et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study , 2008, The Lancet Neurology.
[124] M. Dietlein,et al. Imaging of central nervous system lymphomas with iodine‐123 labeled rituximab , 2005, European journal of haematology.
[125] Darrell Ricke,et al. Absolute quantification of monoclonal antibodies in biofluids by liquid chromatography-tandem mass spectrometry. , 2008, Analytical chemistry.
[126] J. Kovarik,et al. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. , 1999, Transplantation.
[127] T. Vollmer,et al. A phase I trial of an interleukin‐12/23 monoclonal antibody in relapsing multiple sclerosis , 2006, Current medical research and opinion.
[128] M. Czuczman,et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[129] Ivan Nestorov,et al. Clinical pharmacokinetics of tumor necrosis factor antagonists. , 2005, The Journal of rheumatology. Supplement.
[130] M. Albitar,et al. Measuring humanized antibodies in plasma of patients treated with antibody-based therapy using bead-based flow cytometry: the story of alemtuzumab. , 2007, Methods in molecular biology.
[131] T. Schnitzer,et al. CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study. , 1996, British journal of rheumatology.
[132] J. Kovarik,et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[133] R. Figlin,et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[134] A. Gottlieb,et al. Pharmacokinetics and Pharmacodynamics of Multiple Weekly Subcutaneous Efalizumab Doses in Patients With Plaque Psoriasis , 2005, Journal of clinical pharmacology.
[135] M. Tomonaga,et al. Successful Treatment With a Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab) for a Patient With Relapsed Mantle Cell Lymphoma Who Developed a Human Anti-Chimeric Antibody , 2001, International journal of hematology.
[136] Suzanne F. Jones,et al. A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing , 2007, Clinical Cancer Research.
[137] J. Kovarik,et al. Pharmacokinetics and immunodynamics of chimeric IL‐2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients , 1996, Transplant international : official journal of the European Society for Organ Transplantation.
[138] X. Mariette,et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome , 2006, Annals of the rheumatic diseases.
[139] Krys J. Miller,et al. Workshop on Bioanalytical Methods Validation for Macromolecules: Summary Report , 2001, Pharmaceutical Research.
[140] B. Mounho,et al. Concomitant Administration of Bevacizumab, Irinotecan, 5-Fluorouracil, and Leucovorin: Nonclinical Safety and Pharmacokinetics , 2005, International journal of toxicology.
[141] P. Lipsky,et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.
[142] O. Ramilo,et al. Safety and Pharmacokinetics of Palivizumab Therapy in Children Hospitalized with Respiratory Syncytial Virus Infection , 2004, The Pediatric infectious disease journal.
[143] T. Waldmann,et al. Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. , 2006, Leukemia research.
[144] D. Maloney,et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[145] Y. Tsukamoto,et al. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. , 2007, British journal of clinical pharmacology.
[146] E. Raymond,et al. Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. , 2005, European journal of cancer.
[147] D. Maloney,et al. IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma , 1997 .
[148] P. Rutgeerts,et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. , 2008, Gastroenterology.
[149] Mahboob Rahman,et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis , 2007, Annals of the rheumatic diseases.
[150] B. Meibohm,et al. Population Pharmacokinetics of Cetuximab in Patients With Squamous Cell Carcinoma of the Head and Neck , 2008, Journal of clinical pharmacology.
[151] K. Bendtzen,et al. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. , 2007, Rheumatology.
[152] W. Wilson,et al. The pharmacokinetics of rituximab following an intravitreal injection. , 2006, Experimental eye research.
[153] K. Bartz-Schmidt,et al. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn , 2007, Acta ophthalmologica.
[154] H. Kantarjian,et al. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. , 2004, Leukemia research.
[155] A. Gottlieb,et al. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. , 2002, Archives of dermatology.
[156] P. Lipsky,et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. , 2004, Arthritis and rheumatism.
[157] Honghui Zhou,et al. Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis , 2008, Journal of clinical pharmacology.
[158] S. Richards,et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. , 2005, Blood.
[159] L J Kricka,et al. Human anti-animal antibody interferences in immunological assays. , 1999, Clinical chemistry.
[160] K. Aldape,et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. , 2003, Blood.
[161] O. Ramilo,et al. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia , 1998 .
[162] E. Kimby,et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. , 2004, Blood.
[163] R. Pounder,et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha‐4 integrin , 2002, Alimentary pharmacology & therapeutics.
[164] T. Vollmer,et al. Randomized multicenter trial of natalizumab in acute MS relapses , 2004, Neurology.
[165] R. Figlin,et al. Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies , 2008, Clinical Cancer Research.
[166] C. Wagner,et al. Formation, Distribution, and Elimination of Infliximab and Anti-Infliximab Immune Complexes in Cynomolgus Monkeys , 2005, Journal of Pharmacology and Experimental Therapeutics.
[167] J. Jett,et al. A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients , 2004, Supportive Care in Cancer.
[168] B. Dijkmans,et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis , 2007, Annals of the rheumatic diseases.
[169] E. Ezan,et al. Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum. , 2008, Analytical chemistry.
[170] G. Martinelli,et al. High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment , 2007, Journal of Nuclear Medicine.
[171] P. Mclaughlin,et al. Rituximab in indolent lymphoma: the single-agent pivotal trial. , 1999, Seminars in oncology.
[172] C. Ustun,et al. Treatment of a patient with end‐stage renal disease with Rituximab: Pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis , 2002, American journal of hematology.
[173] L. Arcaini,et al. Pharmacokinetic Behavior of Rituximab: A Study of Different Schedules of Administration for Heterogeneous Clinical Settings , 2005, Therapeutic drug monitoring.
[174] A. Kennedy,et al. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. , 2004, Journal of immunological methods.
[175] M. Maurel,et al. Evaluation of a peptide ELISA for the detection of rituximab in serum. , 2007, Journal of immunological methods.
[176] Klemens Scheidhauer,et al. Biodistribution and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[177] P. Bonate,et al. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. , 2007, British journal of clinical pharmacology.
[178] M. Maia,et al. Subretinal bevacizumab detection after intravitreous injection in rabbits. , 2008, Investigative ophthalmology & visual science.
[179] M. Mascelli,et al. Molecular, Biologic, and Pharmacokinetic Properties of Monoclonal Antibodies: Impact of These Parameters on Early Clinical Development , 2007, Journal of clinical pharmacology.
[180] P. Rosenfeld,et al. Promising new treatments for neovascular age-related macular degeneration , 2006, Expert opinion on investigational drugs.
[181] G. Hale,et al. Pharmacokinetics of CAMPATH-1H: assay development and validation. , 2002, Journal of immunological methods.
[182] N. Harbeck,et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier , 2007, Anti-cancer drugs.
[183] C. Piggee. Therapeutic antibodies coming through the pipeline. , 2008, Analytical chemistry.
[184] T. Illidge,et al. A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. , 2004, Blood.
[185] Binodh DeSilva,et al. Key elements of bioanalytical method validation for macromolecules , 2007, The AAPS Journal.
[186] J. Berlin,et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer , 2007, Cancer.
[187] R H Wheeler,et al. Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[188] A. Gottlieb,et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. , 2004, The Journal of investigative dermatology.
[189] Lars Bäckman,et al. INTERLEUKIN-2-RECEPTOR BLOCKADE WITH DACLIZUMAB TO PREVENT ACUTE REJECTION IN RENAL TRANSPLANTATION , 1998 .
[190] D. Abendroth,et al. Screening for basiliximab exposure–response relationships in renal allotransplantation , 1999, Clinical transplantation.
[191] E. Van Cutsem,et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[192] J. Kovarik,et al. Pharmacokinetics and Immunodynamics of Basiliximab in Pediatric Renal Transplant Recipients on Mycophenolate Mofetil Comedication , 2008, Transplantation.
[193] J. Fridlyand,et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[194] D. Podoloff,et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[195] S. Ogawa,et al. Pharmacokinetics of alemtuzumab after haploidentical HLA‐mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab with or without CD52‐positive malignancies , 2006, American journal of hematology.